This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
The most effective weight loss peptide in clinical research. Tirzepatide activates both GIP and GLP-1 receptors simultaneously — producing 20–22% average body weight reduction that outperforms every previous pharmacological weight loss intervention.
Tirzepatide is a first-in-class dual incretin receptor agonist, simultaneously activating both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (gastric inhibitory polypeptide) receptor. Developed by Eli Lilly and approved by the FDA as Mounjaro (diabetes, 2022) and Zepbound (weight loss, 2023), it represents a significant advance over single-pathway GLP-1 agonists.
GIP and GLP-1 work through complementary mechanisms. GLP-1 suppresses appetite and slows gastric emptying. GIP enhances insulin secretion, improves insulin sensitivity in adipose tissue, and may reduce the nausea associated with GLP-1 alone — one reason tirzepatide is often better tolerated than semaglutide at equivalent weight loss doses.
The SURMOUNT-1 trial showed 22.5% average body weight reduction at the highest dose over 72 weeks — the largest weight loss ever recorded in a Phase 3 pharmacological trial. A direct head-to-head comparison (SURMOUNT-5) showed tirzepatide produced 47% more weight loss than semaglutide at maximum doses.
22.5% average body weight reduction at maximum dose — surpassing semaglutide, liraglutide, and every prior pharmacological intervention in head-to-head and independent trials.
GIP receptor activation improves insulin sensitivity in adipose and muscle tissue — addressing metabolic dysfunction at the root level rather than just appetite suppression.
Clinical data shows tirzepatide users report less severe nausea than semaglutide at equivalent weight loss doses — likely due to GIP's modulatory effect on GLP-1-induced GI effects.
Dual receptor activation increases energy expenditure beyond appetite reduction alone — a metabolic shift contributing to the larger weight loss outcomes vs GLP-1-only therapies.
Significant improvements in HbA1c, triglycerides, blood pressure, and waist circumference — comprehensive cardiometabolic benefit beyond weight loss alone.
Subcutaneous injection once per week — same convenient dosing schedule as semaglutide, with substantially greater average weight loss outcomes.
Tirzepatide follows the same gradual escalation principle as semaglutide — starting at the lowest dose and titrating upward every 4 weeks. The dose escalation schedule follows Zepbound/Mounjaro labeling.
| Week | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg weekly | Initiation dose |
| Weeks 5–8 | 5 mg weekly | First therapeutic dose; many see results here |
| Weeks 9–12 | 7.5 mg weekly | — |
| Weeks 13–16 | 10 mg weekly | — |
| Weeks 17–20 | 12.5 mg weekly | — |
| Week 21+ | 15 mg weekly | Max dose; highest average weight loss in trials |
| Route | Subcutaneous — abdomen, upper thigh, or upper arm | |
N=2539, 72 weeks. The 15mg cohort achieved 22.5% average body weight reduction — the largest ever recorded in a Phase 3 weight loss trial. The 5mg and 10mg cohorts achieved 15.0% and 19.5% respectively.
First head-to-head comparison of tirzepatide vs semaglutide (both at maximum doses) showed tirzepatide produced 47% more weight loss — 20.2% vs 13.7% — the clearest evidence of tirzepatide's superiority.
The SURPASS trial series (6 trials) established tirzepatide's superiority over semaglutide, insulin glargine, and other diabetes medications for HbA1c reduction and weight loss in T2DM patients.
Mechanistic studies show GIP receptor activation improves insulin sensitivity in adipose tissue and modulates the GI side effects of GLP-1 activation — explaining both the superior efficacy and improved tolerability profile vs semaglutide.
Both are once-weekly subcutaneous GLP-1-based peptides. Tirzepatide adds GIP receptor agonism for superior outcomes.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GLP-1 + GIP (dual) | GLP-1 only |
| Average weight loss (max dose) | ~22.5% | ~14.9% |
| Dosing | Once weekly SC | Once weekly SC |
| Max approved dose | 15 mg | 2.4 mg |
| Nausea profile | Generally lower than semaglutide | Higher at comparable efficacy doses |
| Evidence base | Large Phase 3 program | Larger overall (longer on market) |
Tirzepatide activates GIP receptors in addition to GLP-1 receptors. GIP improves insulin sensitivity in adipose tissue and increases energy expenditure through mechanisms that GLP-1 alone doesn't activate. The combination creates additive and potentially synergistic effects on body weight — which is why SURMOUNT-5 showed 47% more weight loss vs semaglutide head-to-head.
Clinical data and real-world reports generally favor tirzepatide on tolerability at equivalent weight loss doses. The GIP component appears to modulate some of the GI effects of GLP-1 activation. Individual response varies, but head-to-head data shows lower GI discontinuation rates for tirzepatide.
Yes — transitioning from semaglutide to tirzepatide is a documented clinical practice. The typical approach is to start tirzepatide at 5mg the week after the last semaglutide dose, then titrate normally. Some protocols start lower (2.5mg) for extra tolerance margin.
Retatrutide (GLP-1 + GIP + glucagon triple agonist) is currently in Phase 3 FDA trials with Eli Lilly. Phase 2 data showed 24.2% weight loss — potentially exceeding tirzepatide. It remains a research compound (not yet approved) and is not currently in the Cinch Bio catalog. We'll add it when supply quality and the regulatory picture are clear.
Tirzepatide is sold for research purposes only. While FDA-approved in pharmaceutical form (Mounjaro, Zepbound), research peptide tirzepatide is not an FDA-approved drug and should not substitute for physician-prescribed treatment. This information is educational and does not constitute medical advice. Consult a qualified healthcare professional before any GLP-1 protocol.
Availability Notice: GLP-1 receptor agonists including tirzepatide currently require physician coordination and are available by waitlist only. Join below to be notified when your protocol is ready.
GLP-1 protocols require physician review and compounding pharmacy coordination. Submit your intake — our team will contact you when your protocol is confirmed and ready to ship.
Join the WaitlistMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.